Cue Biopharma Operating Income Over Time
| CUE Stock | USD 0.28 0 0.64% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cue Biopharma Performance and Cue Biopharma Correlation. Will Biotechnology sector continue expanding? Could Cue diversify its offerings? Factors like these will boost the valuation of Cue Biopharma. Projected growth potential of Cue fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cue Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.41) | Revenue Per Share | Quarterly Revenue Growth (0.36) | Return On Assets | Return On Equity |
Cue Biopharma's market price often diverges from its book value, the accounting figure shown on Cue's balance sheet. Smart investors calculate Cue Biopharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Cue Biopharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cue Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cue Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare Cue Biopharma and related stocks such as NRX Pharmaceuticals, OUTLOOK THERAPEUTICS INC, and Equillium Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRXP | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (1 M) | (713.2 K) | (22.1 M) | (95.2 M) | (44.3 M) | (27.6 M) | (19.7 M) | (17.7 M) | (18.6 M) |
| OTLK | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (46.6 M) | (51.3 M) | (35.9 M) | (29.6 M) | (36.3 M) | (36.8 M) | (51.7 M) | (63.1 M) | (53.1 M) | (71.7 M) | (67.1 M) | (60.4 M) | (63.4 M) |
| EQ | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (8.6 M) | (26.7 M) | (29.5 M) | (37.8 M) | (62.1 M) | (14.5 M) | (8.3 M) | (7.4 M) | (7.8 M) |
| COEP | (10.1 K) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (14 M) | (34.2 M) | (21.5 M) | (10.1 M) | (9 M) | (9.5 M) |
| SPRB | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (10 M) | (13.1 M) | (29.4 M) | (42.1 M) | (47.3 M) | (52 M) | (56.2 M) | (50.5 M) | (53.1 M) |
| IOBT | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (10.1 M) | (41.2 M) | (71.4 M) | (91.4 M) | (95.2 M) | (85.7 M) | (81.4 M) |
| IPSC | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (49.2 M) | (94.9 M) | (133.8 M) | (146.5 M) | (138.1 M) | (124.3 M) | (130.5 M) |
| SNTI | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (24.7 M) | (40.4 M) | (70.6 M) | (92.7 M) | (61 M) | (54.9 M) | (57.7 M) |
| BRNS | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (20 M) | (45.2 M) | (4 M) | (83.9 M) | (68 M) | (61.2 M) | (64.2 M) |
Cue Biopharma and related stocks such as NRX Pharmaceuticals, OUTLOOK THERAPEUTICS INC, and Equillium Operating Income description
Operating Income is the amount of profit realized from Cue Biopharma operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cue Biopharma is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Cue Biopharma | CUE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 40 Guest Street, |
| Exchange | NASDAQ Exchange |
USD 0.2818
Check out Cue Biopharma Performance and Cue Biopharma Correlation. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Cue Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.